| ATOSSA THERAPEUTICS |
| USA |
| Gesundheit |
| US04962H5063 / A2JJ99 |
| YAG2 (Frankfurt) / ATOS (NASDAQ) |
| FRA:YAG2, ETR:YAG2, YAG2:GR, NASDAQ:ATOS |
| - |
| https://atossatherapeutic.. |
|
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company developing investigational medicines in oncology and other areas of significant unmet medical need. Its primary focus centers on (Z)-Endoxifen, a proprietary oral selective estrog..
>Volltext.. |
| 40.02 Mio. EUR |
| 4.15 Mio. EUR |
| - |
| -32.16 Mio. EUR |
| -30.12 Mio. EUR |
| -3.5 EUR |
| - |
| 35.87 Mio. EUR |
| -25.78 Mio. EUR |
| 5.02 |
| - |
| -36.33% |
| - |
| - |
| - |
| - |
| ATOSSA |
| 04.04.26 |
|